Discovery and Biological Evaluation of Novel, Potent, and Orally Available CBLB Inhibitors
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c02541 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Fanye Meng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Insilico Medicine Shanghai Ltd, Suite 902, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-cbl, Drug Discovery, Adaptor Proteins, Signal Transducing, Antineoplastic Agents. Die Arbeit nennt 54 Literaturangaben.
Abstract (Originalsprache)
Casitas B-lineage lymphoma-b (CBLB) has emerged as a promising therapeutic target for cancer immunotherapy due to its central role in modulating T-cell activation and immune tolerance. In this work, we employed a structure-guided drug discovery approach, leveraging the cocrystal structure of CBLB with the hit compound to systematically optimize potency, selectivity, and pharmacokinetic profiles. Through iterative structure-activity relationship (SAR) exploration, we identified compound 10, which is a potent and orally bioavailable CBLB inhibitor with favorable ADME properties. In vivo studies demonstrated that compound 10 exhibits significant antitumor efficacy in syngeneic mouse models, synergizes strongly with anti-PD-1 therapy to enhance tumor regression, and induces durable immune memory against tumor rechallenge. Comprehensive PK/PD analyses revealed sustained target engagement and dose-dependent modulation of downstream biomarkers. Our detailed SAR elucidation provides a roadmap for further optimization of CBLB inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Insilico Medicine Shanghai Ltd, Suite 902, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China.
- Insilico Medicine Hong Kong Ltd., Hong Kong 999077, China.
- Insilico Medicine AI Limited, Masdar City, Abu Dhabi 145748, UAE.
ORCID-Profile: Fanye Meng, Alex Aliper, Feng Ren, Xiao Ding, Alex Zhavoronkov
Zitieren
APA
Meng, F., Cao, Z., Liu, J., Wang, Y., Ning, Z., Yu, J., Fan, Y., Chen, S., Zhang, M., Pun, F. W., Aliper, A., Ren, F., Cai, X., Ding, X., & Zhavoronkov, A. (2025). Discovery and Biological Evaluation of Novel, Potent, and Orally Available CBLB Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02541
Vancouver
Meng F, Cao Z, Liu J, Wang Y, Ning Z, Yu J, et al. Discovery and Biological Evaluation of Novel, Potent, and Orally Available CBLB Inhibitors. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c02541
BibTeX
@article{Meng2025,
author = {Meng, Fanye and Cao, Zhongying and Liu, Jinxin and Wang, Yazhou and Ning, Zhilin and Yu, Jiaojiao and Fan, Yaya and Chen, Shan and Zhang, Man and Pun, Frank W and Aliper, Alex and Ren, Feng and Cai, Xin and Ding, Xiao and Zhavoronkov, Alex},
title = {Discovery and Biological Evaluation of Novel, Potent, and Orally Available CBLB Inhibitors},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c02541}
}
EUVIMED